孟鲁司特联合吸入沙美特罗替卡松对支气管哮喘治疗的临床价值分析

Clinical Value of Montelukast Combined with Inhaled Salmeterol Ticasone for Treatment of Bronchial Asthma

目的关于孟鲁司特+吸入沙美特罗替卡松治疗支气管哮喘的临床效果评价。方法将2018年1月至2019年10月来我院开展治疗的66例支气管哮喘患者随机分为观察组和对照组,每组33例。观察组行孟鲁司特+吸入沙美特罗替卡松方法进行治疗研究,对照组行单纯的沙美特罗替卡松吸入治疗进行研究,分别计算两组相关数据统计结果,并做统计学比较。结果观察组的治疗有效率高于对照组,不良反应发生率低于对照组,差异有统计学意义(P<0.05);观察组肺功能改善情况优于对照组,差异有统计学意义(P<0.05)。结论临床治疗支气管哮喘的时候应用孟鲁斯特+吸入沙美特罗替卡松所取得的治疗效果明显优于单纯吸入沙美特罗替卡松的效果,值得推荐。

Objective To evaluate the clinical effect of montelukast and inhaled salmeterol ticasone on bronchial asthma.Methods From January 2018 to October 2019,66 patients with bronchial asthma who came to our hospital for treatment were randomly divided into the observation group and the control group,33 cases in each group.The observation group was treated with montelukast+inhaled salmeterol ticasone,and the control group was treated with simple salmeterol ticasone inhalation.The statistical results of the two groups were calculated and compared statistically.Results The effective rate of treatment in the observation group was higher than that of the control group,the incidence of adverse reactions was lower than that of the control group,the difference was statistically significant(P<0.05);the observation group improvement of lung function was better than that of the control group,the difference was statistically significant(P<0.05).Conclusion The therapeutic effect of montelukast+inhaled salmeterol ticasone in the clinical treatment of bronchial asthma is significantly better than that of salmeterol inhaled ticasone alone,and it is worth recommending.